Vyndamax FDA Approval History
Last updated by Judith Stewart, BPharm on Oct 2, 2019.
FDA Approved: Yes (First approved May 3, 2019)
Brand name: Vyndamax
Generic name: tafamidis
Dosage form: Capsules
Company: Pfizer Inc.
Treatment for: Cardiomyopathy of Transthyretin-Mediated Amyloidosis
Vyndamax (tafamidis) is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis.
Development timeline for Vyndamax
| Date | Article |
|---|---|
| May 6, 2019 | Approval FDA Approves New Treatments Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) for Heart Disease Caused by Transthyretin Mediated Amyloidosis |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
